Daniel Takash

@takash
76 Followers
104 Following
75 Posts
Last name rhymes with “brackish.”
JD candidate at University of Michigan Law. Formerly regulatory policy fellow at the Niskanen Center.
Working on IP, open society, and executing a passable swing-out.
🦔>🦊
Intellectual property law is designed to protect knowledge from the free-rider problem, but critics suggest it gives firms monopoly power. Both views are oversimplified.
https://www.niskanencenter.org/antitrust-problems-in-patents-and-copyrights-a-primer-for-policymakers/
Antitrust problems in patents and copyrights: A primer for policymakers - Niskanen Center

When policymakers hear about IP at all, it is generally from misleading viewpoints that can be placed between two extremes. At one end is the notion that intellectual property anywhere and everywhere creates monopoly. At the other is a “nothing to see here” approach that treats market concentration and market power as rare exceptions in the IP world. In reality, the interplay between grants of exclusive rights and competition is complicated and evades simple classification.

Niskanen Center - Improving Policy, Advancing Moderation

Pictures from Vilnius, site of the NATO summit.

“No more Munichs, no more Yaltas.”

Welcome to the bunker, new Mastodon users.
Today is 🇱🇹 Mourning and Hope day. It’s the 82nd anniversary of the first deportations to Siberia from the Baltic States by the USSR as part of their campaign of subjugation and oppression of their neighbors.
IP people to tech policy people today:
D35,851 - issued in 1902 for a design for a "Watch Case." #DesignPatents #Easter
RT @JimSwiftDC
How Rod Dreher Caused an International Scandal in Eastern Europe https://www.thebulwark.com/how-rod-dreher-caused-an-international-scandal-in-eastern-europe/ via @bulwarkonline
How Rod Dreher Caused an International Scandal in Eastern Europe

Blogging and backtracking.

The Bulwark
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System

AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.